Sanofi
Cambodia, one of the leading pharmaceutical companies in Cambodia, introduced a
new vaccine so-called Imojev, a vaccine against JE, to Cambodia’s market with
participation of more than 200 healthcare professionals.
Vaccination
against JE should occur before exposure to risk. For people living in endemic
regions, this should be in early childhood. Imojev can be administered as early
as nine months of age. It can also be used in adults in endemic regions or
travelers, and has a rapid onset of protection.
On this
occasion, Mr. Tomas Gaudry, Vaccine Head of Vietnam and Cambodia, said during
the event at the Sokha hotel that “Japanese Encephalitis (JE) has also been
identified as a major cause of neurological disabilities. At least 50 percent
of children who survive the illness are left with severe consequences,
including physical, cognitive, or psychiatric problems which are life-long for
most victims. There are an estimated 60,000 clinical cases and 15,000 deaths
annually in the Asia regions, which caused by JE.”
Doctor
Alain Bouckenooghe Dr Bouckenooghe, Associate VP and Regional Head of Clinical
R&D Sanofi Pasteur, Asia Pacific hub, also explained that this illness is
not transmitted from human to human but only through a particular species of
mosquitos. Symptoms include high-grade fever, nausea, vomiting, altered sensory
experiences, convulsions, neck stiffness, muscular rigidity and abnormal
movements.
Infants
from age 9 months to 60 years old can be vaccinatted against JE. Injections
against JE need to be administered by professional doctors.
Head of
Sanofi Cambodia, Ms. Minh said, “The new product launched today proves that
Sanofi is continuing its commitment to make more quality products available for
the country’s healthcare needs. Sanofi also closely collaborates with
healthcare professionals to bring better and safer prevention methods to
Cambodian people, especially children.”
No comments:
Post a Comment